Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.

Abstract

A large alkaptonuria (AKU) cohort was studied to better characterize the poorly understood spondyloarthropathy of rare disease AKU. Eighty-seven patients attended the National Alkaptonuria Centre (NAC) between 2007 and 2020. Seven only attended once. Fifty-seven attended more than once and received nitisinone 2 mg daily. Twenty-three attended at least twice without receiving nitisinone. Assessments included questionnaire analysis, 18F Positron emission tomography computerised tomography (PETCT), as well as photographs of ochronotic pigment in eyes and ears at baseline when 2 mg nitisinone was commenced and yearly thereafter. Blood and urine samples were collected for chemical measurement. The prevalence of ochronosis, as well as pain, PETCT and combined pain and PETCT scores, was greatly increased at 90.5%, 85.7%, 100%, and 100%, respectively. Joint pain scores were greatest in proximal joints in upper and lower limbs. PETCT joint scores were higher in proximal joints in upper limb but higher in distal joints in the lower limb. Spine pain scores were highest in lumbar, followed by cervical, thoracic, and cervical regions at 77.4%, 59.5%, 46.4%, and 25%, respectively. PETCT spine scores were highest in thoracic followed by lumbar, cervical, and sacroiliac regions at 74.4%, 70.7%, 64.6%, and 47.8% respectively; ochronosis associated closely with spondyloarthropathy scores (R = .65; P < .0001). Nitisinone reversed ochronosis significantly, with a similar pattern of decreased joint and spine disease. Spondyloarthropathy is a highly prevalent feature in this NAC cohort. Ochronosis appears to be associated with spondyloarthropathy. Nitisinone decreases ochronosis and had a similar nonsignificant effect pattern on spondyloarthropathy.

• Authors: Lakshminarayan R Ranganath, Milad Khedr, Sobhan Vinjamuri, James A Gallagher
• Journal: Journal of inherited metabolic disease (J Inherit Metab Dis) Vol. 44 Issue 3 Pg. 666-676 (05 2021) ISSN: 1573-2665 [Electronic] United States
• PMID: 33452825 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 SSIEM.

Chemical References

• Cyclohexanones
• Nitrobenzoates
• nitisinone
• Homogentisic Acid

Topics

• Aged
• Alkaptonuria (drug therapy, metabolism)
• Cohort Studies
• Cyclohexanones (administration & dosage)
• Female
• Homogentisic Acid (metabolism)
• Humans
• Joints (diagnostic imaging, pathology)
• Linear Models
• Male
• Middle Aged
• Nitrobenzoates (administration & dosage)
• Ochronosis (drug therapy, metabolism)
• Phenotype
• Positron Emission Tomography Computed Tomography
• Severity of Illness Index
• Spine (diagnostic imaging, pathology)
• United Kingdom